IBD-PODCAST Spain : A Close Look at Current Daily Clinical Practice in IBD Management
© 2024. The Author(s)..
BACKGROUND: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible bowel damage and long-term complications, reduced quality of life, invalidity, and economic burden. Suboptimal control of IBD is associated with higher healthcare resource utilization (HCRU), impaired quality of life (QoL), and reduced work productivity.
AIMS: The IBD-PODCAST study aimed to assess the proportion of IBD patients with suboptimal control and its associated impact.
METHODS: IBD-PODCAST is a cross-sectional, multicenter study that aimed to characterize the CD and UC population with optimal or suboptimal control according to the STRIDE-II criteria and patient- and physician-reported measures. Here we present the results of the Spanish cohort (n = 396).
RESULTS: A total of 104/196 (53.1%) CD and 83/200 (41.5%) UC patients were found to have suboptimal disease control. Long-term treatment targets according to STRIDE-II were applied in 172 (87.8%) CD and 181 (90.5%) UC patients. 125 of 172 (72.7%) CD and 74 of 181 (40.9%) UC patients were currently treated with targeted immunomodulators. Patients with CD and UC and suboptimal disease control showed impaired QoL, higher HCRU and direct costs, and also loss of work productivity compared to those with optimal control.
CONCLUSION: Despite a high rate of targeted immunomodulator therapy, a substantial proportion of IBD patients show suboptimal disease control according to the STRIDE II criteria. Those patients with suboptimal disease control exhibit impaired QoL, less work productivity, and higher HCRU, suggesting that there is considerable need for better treatment approaches in IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Digestive diseases and sciences - 69(2024), 3 vom: 31. März, Seite 749-765 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vega, P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Crohn’s disease |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10620-023-08220-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367082306 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367082306 | ||
| 003 | DE-627 | ||
| 005 | 20240326235233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10620-023-08220-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM367082306 | ||
| 035 | |a (NLM)38217680 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vega, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IBD-PODCAST Spain |b A Close Look at Current Daily Clinical Practice in IBD Management |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible bowel damage and long-term complications, reduced quality of life, invalidity, and economic burden. Suboptimal control of IBD is associated with higher healthcare resource utilization (HCRU), impaired quality of life (QoL), and reduced work productivity | ||
| 520 | |a AIMS: The IBD-PODCAST study aimed to assess the proportion of IBD patients with suboptimal control and its associated impact | ||
| 520 | |a METHODS: IBD-PODCAST is a cross-sectional, multicenter study that aimed to characterize the CD and UC population with optimal or suboptimal control according to the STRIDE-II criteria and patient- and physician-reported measures. Here we present the results of the Spanish cohort (n = 396) | ||
| 520 | |a RESULTS: A total of 104/196 (53.1%) CD and 83/200 (41.5%) UC patients were found to have suboptimal disease control. Long-term treatment targets according to STRIDE-II were applied in 172 (87.8%) CD and 181 (90.5%) UC patients. 125 of 172 (72.7%) CD and 74 of 181 (40.9%) UC patients were currently treated with targeted immunomodulators. Patients with CD and UC and suboptimal disease control showed impaired QoL, higher HCRU and direct costs, and also loss of work productivity compared to those with optimal control | ||
| 520 | |a CONCLUSION: Despite a high rate of targeted immunomodulator therapy, a substantial proportion of IBD patients show suboptimal disease control according to the STRIDE II criteria. Those patients with suboptimal disease control exhibit impaired QoL, less work productivity, and higher HCRU, suggesting that there is considerable need for better treatment approaches in IBD | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a Inflammatory bowel diseases | |
| 650 | 4 | |a STRIDE II recommendations | |
| 650 | 4 | |a Treat to target strategy | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Huguet, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, E |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio, S |e verfasserin |4 aut | |
| 700 | 1 | |a Suarez, P |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, M I |e verfasserin |4 aut | |
| 700 | 1 | |a Paredes, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Camba, A |e verfasserin |4 aut | |
| 700 | 1 | |a Plaza, R |e verfasserin |4 aut | |
| 700 | 1 | |a Mañosa, M |e verfasserin |4 aut | |
| 700 | 1 | |a Pajares, R |e verfasserin |4 aut | |
| 700 | 1 | |a Sicilia, B |e verfasserin |4 aut | |
| 700 | 1 | |a Madero, L |e verfasserin |4 aut | |
| 700 | 1 | |a Kolterer, S |e verfasserin |4 aut | |
| 700 | 1 | |a Leitner, C |e verfasserin |4 aut | |
| 700 | 1 | |a Heatta-Speicher, T |e verfasserin |4 aut | |
| 700 | 1 | |a Michelena, N |e verfasserin |4 aut | |
| 700 | 1 | |a Santos de Lamadrid, R |e verfasserin |4 aut | |
| 700 | 1 | |a Dignass, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gomollón, F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d 1989 |g 69(2024), 3 vom: 31. März, Seite 749-765 |w (DE-627)NLM000356492 |x 1573-2568 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2024 |g number:3 |g day:31 |g month:03 |g pages:749-765 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10620-023-08220-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2024 |e 3 |b 31 |c 03 |h 749-765 | ||